Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges
about
Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal managementPotential role of tedizolid phosphate in the treatment of acute bacterial skin infectionsCurrent updates on oxazolidinone and its significanceNew developments in the management of severe skin and deep skin structure infections - focus on tedizolidA potent synthetic inorganic antibiotic with activity against drug-resistant pathogensTedizolid Phosphate: a Next-Generation Oxazolidinone.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Tedizolid phosphate.Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionLack of neuropathological changes in rats administered tedizolid phosphate for nine months.Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniaeStability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration.Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia modelAdvances in MRSA drug discovery: where are we and where do we need to be?Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.Antibiotics in development targeting protein synthesis.Tedizolid (TR-701): a new oxazolidinone with enhanced potency.Prospects for new antibiotics: a molecule-centered perspective.Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials.Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.Tedizolid for treatment of acute bacterial skin and skin structure infections.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Linezolid Resistance in Staphylococci.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infectionsPharmacokinetics of Tedizolid in Obese and Nonobese Subjects.In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections.Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone.Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea.Identification of potential antimicrobials against Salmonella typhimurium and Listeria monocytogenes using Quantitative Structure-Activity Relation modeling.Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.
P2860
Q26798630-FB740063-FCA6-428E-A3FF-D70BFD3BFDA1Q26853612-46415906-0417-43FD-8DF9-E627A74A1D06Q26995628-9A1DDC44-9DC6-4101-8DD1-E1B6914A9CA8Q28083116-C2DC32B4-0B70-4134-817B-53A33126885FQ28817444-6FC573D6-FBC9-45EC-AF40-E306E461584FQ33420646-0B65B3E2-C1E2-4CA3-9A67-D4D12EE208A5Q33438834-E97C0EB4-EA0C-4CFD-818B-CCD585D7E2A6Q34612944-F2EADF52-CFC6-4C51-A81E-7164B5C705F9Q34922189-C21AA752-272B-4D4D-B28E-1885EBFEECF8Q34922770-1CA447E8-3D3D-4D5C-BFA8-9BA69361F77BQ35941253-76A4F2A0-92B4-480E-8F0B-BEEE75C9A6E7Q36171683-72F3687D-B1C3-43AB-A638-642298DFB15DQ36172450-09719488-423E-4C8E-A49C-7B9697C64723Q36172558-2404A2B6-7007-4652-9CCE-CE0AA1E89A34Q36327804-B4946994-F202-4CCC-8170-D62A0C3D47C0Q36364009-06855582-13DE-4BF9-A6C6-B1CD16AE3AB7Q37112508-C5353732-9478-48E7-B75A-762D1FA2D585Q37538738-1D9824FA-6DAB-41E2-BAD3-792DB58CA6D0Q37970724-8B5AE497-BE7D-43D7-8B0D-C0F93A8761C2Q37983130-6858B11C-66E2-4356-8302-BE2AD438623DQ38113689-7E1C058A-5C2B-4777-A2C4-E6ED0310B1DBQ38171760-CB46329A-C226-4F59-9E7B-4AE1D04EA625Q38255366-9E757225-5E30-4761-985D-933406CCB37BQ38347869-CB7C5FCA-817E-46EB-91D6-C2C0BD99FA5CQ38352171-E0C2D33A-EFA7-42CF-B2B1-DE02135176FFQ38379887-E142F12C-7174-4A19-A251-851B83B3D767Q38536296-94A287D5-536A-4AFB-BAD3-AE6A3264C7BFQ38554583-F25773A6-E3D9-4C4B-B129-393B9358AC20Q38958278-2A4281B9-6870-455D-93C1-7549BD2C9435Q38974364-10958A6A-3439-4E02-B271-D051E128EFB2Q39067666-478109D8-AACC-4974-9FBC-A065BF0C8B1CQ40210571-A10110ED-0654-4325-966F-7022CE30C6D8Q40284949-A1208176-8029-44A0-BF78-78D8D533A5F5Q40947815-C3F173F3-C855-4D01-A529-E1DCE3B1FC50Q41655310-424B9F26-C32A-4C01-B8F2-2F15CD1D63C2Q41732849-ADC0DEA2-7492-4FDB-B1C7-E187BE190CD4Q41881874-5D6A9DC1-8734-4C4A-9804-D44D5E872ADAQ42111215-BB3A2359-CCFF-4D01-AD7A-C4026C9ED42CQ47134841-E41B2F2E-A2E6-4506-867F-F27539367320Q49446863-2D1FF257-2EE5-4C22-B672-33B6936A4542
P2860
Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Comparative in vitro antimicro ...... ia, and quality control ranges
@en
type
label
Comparative in vitro antimicro ...... ia, and quality control ranges
@en
prefLabel
Comparative in vitro antimicro ...... ia, and quality control ranges
@en
P2860
P356
P1476
Comparative in vitro antimicro ...... ia, and quality control ranges
@en
P2093
Maria M Traczewski
Steven D Brown
P2860
P304
P356
10.1128/AAC.01569-09
P407
P577
2010-03-15T00:00:00Z